Argos Therapeutics Inc (NASDAQ:ARGS) insider Charles A. Nicolette sold 100,250 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $0.16, for a total transaction of $16,040.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Argos Therapeutics Inc (ARGS) remained flat at $$0.16 on Friday. The company had a trading volume of 2,657,991 shares, compared to its average volume of 3,280,000. The company has a debt-to-equity ratio of -1.46, a current ratio of 2.29 and a quick ratio of 2.29. Argos Therapeutics Inc has a 12 month low of $0.13 and a 12 month high of $5.50. The firm has a market capitalization of $14.32, a price-to-earnings ratio of -0.15 and a beta of 1.38.

An institutional investor recently bought a new position in Argos Therapeutics stock. Wasatch Advisors Inc. bought a new position in Argos Therapeutics Inc (NASDAQ:ARGS) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned about 1.21% of Argos Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 18.35% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Argos Therapeutics Inc (ARGS) Insider Sells $16,040.00 in Stock” was first published by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with's FREE daily email newsletter.